Evidence map›Paper›PMID 42079184›Full record

ArticlebioRxiv : the preprint server for biology2026

Defects in CD8

Kristin N Weinstein, Zoe H Bishop, Elya A Shamskhou, Finnegan N Barry, Harshini Chandrashekar, Gabriela Verdezoto, Marissa de Leon, Joseph R Albe, Andrew Koval, Baohua Zhou and 4 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Kristin N WeinsteinCenter for Fundamental Immunology, Benaroya Research Institute; Seattle, USA.ORCID 0000-0002-9257-951X
Zoe H BishopCenter for Fundamental Immunology, Benaroya Research Institute; Seattle, USA.
Elya A ShamskhouDepartment of Immunology, University of Washington; Seattle, USA.
Finnegan N BarryCenter for Fundamental Immunology, Benaroya Research Institute; Seattle, USA.
Harshini ChandrashekarCenter for Fundamental Immunology, Benaroya Research Institute; Seattle, USA.
Gabriela VerdezotoDepartment of Immunology, University of Washington; Seattle, USA.
Marissa de LeonCenter for Fundamental Immunology, Benaroya Research Institute; Seattle, USA.
Joseph R AlbeCenter for Fundamental Immunology, Benaroya Research Institute; Seattle, USA.
Andrew KovalCenter for Fundamental Immunology, Benaroya Research Institute; Seattle, USA.
Baohua ZhouDepartment of Microbiology and Immunology, Indiana University School of Medicine; Indianapolis, USA.
Phillip P DomeierCenter for Fundamental Immunology, Benaroya Research Institute; Seattle, USA.
Michael Y GernerDepartment of Immunology, University of Washington; Seattle, USA.
Daniel CampbellCenter for Fundamental Immunology, Benaroya Research Institute; Seattle, USA.ORCID 0000-0002-9652-7178
Steven F ZieglerCenter for Fundamental Immunology, Benaroya Research Institute; Seattle, USA.

Funding

cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
Foxp3 isoform expression and regulation of autoantibody productionR01AI188364 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI Daniel J Campbell · 2025 to 2026
$1.4M
Foxp3 isoforms and IgE-mediated UVB-induced skin inflammation expressionR21AI178426 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI ZIEGLER, STEVEN F · 2023 to 2024
$477k
NHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIAID NIH HHS R01 AI188364NIAID NIH HHS R21 AI178426NIDA NIH HHS 75N95020D00005NIH HHS 75N93023D00005NIH HHS 75N99020D00005
6 · The paper itself

Abstract

Regulatory T cells (Tregs) prevent autoimmunity through suppressive functions largely programmed by the transcription factor FOXP3. Healthy humans express approximately equivalent levels of two major alternatively spliced isoforms of FOXP3: a full-length version containing all coding exons (FOXP3-FL) and a version lacking exon 2 (FOXP3-ΔE2). However, sole FOXP3-ΔE2 expression causes lethal IPEX syndrome, and the FOXP3-ΔE2 isoform is elevated in several autoimmune diseases. These observations strongly suggest defects in suppression by FOXP3-ΔE2 Tregs which we investigated here using Foxp3-ΔE2 mice. In an influenza virus infection model, Foxp3-ΔE2 mice had an increased magnitude of the CD8

Identifiers

PMID42079184
PMCPMC13131781

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.